Figure 4.

Assay for effects of ANGPTL7 or anti-ANGPTL7 on outflow facility. (A) A dose-responsive decrease in outflow facility was seen in the bioengineered 3D-HTM/HSC tissue model at concentrations of 0.56, 1.1, and 3.3 nM of recombinant ANGPTL7 (25, 50, and 150 ng/mL, respectively; n = 3 donors, run in triplicate; *P < 0.05 vs. vehicle control; #P < 0.05 vs. Dex, one-way ANOVA with Tukey's multiple comparison test). (B) Donor 2 was selected for its superior response to ANGPTL7 at 1.1 nM. Antibodies were added at 10× molar excess at 11 nM. Both Dex and ANGPTL7 reduced outflow facility, and the isotype antibody control had minimal effects. Several antibodies (AAb-1–AAb-19) targeting ANGPTL7 eliminated the reduction in outflow facility (n = 3; *P < 0.05, **P < 0.005 vs. treatment with ANGPTL7 + isotype control antibody, ANOVA with Holm–Sidak's multiple comparison test). Data are shown as mean ± SEM.